What we are researching
The purpose of this study is to learn about the safety and tolerability of the study medicine in people, living with hemophilia A.
Who may participate
Each clinical trial has its own requirements for who can participate, often called eligibility criteria. Some of the key criteria for this study are listed here. Discuss these requirements with your study doctor to determine if you may be eligible to participate. Additional criteria for your doctor to review can be found here NCT07220564.
Hemophilia A
Have been diagnosed with congenital haemophilia A, with factor VIII (FVIII) activity less than or equal to 15% with or without FVIII inhibitors
And not currently on prophylaxis treatment
Body Weight
Have a body weight of at least 45 kgs (about 99 lbs) and a body mass index (BMI) of less than 30
Sex
Male
Age
18 to 64 years
Study Medicine
1 to 2 tablets by mouth daily
Number of study visits
About 17 visits over a period of about 11 weeks
What to expect
If your study doctor determines that you are eligible and you decide to participate, you will be enrolled into the study.
Once enrolled, you will be assigned to receive the study medicine at one of three dose levels. All doses will be given as a tablet that you will take by mouth.
Your participation is expected to last about 11 weeks, with a mix of in-person and phone visits every day during the treatment period followed by in-person visits every 6-10 days during the follow-up period. Visits may include physical exams and lab tests to monitor your health and safety.
Call 866-867-7178 or email clinicaltrials@novonordisk.com to learn more
about the study and find out whether there is a participating study site near you.
When you call, please reference study 8454 or VOYAGER 2
You may also choose to discuss this clinical trial with your healthcare provider.